CD99 is frequently expressed in disease-initiating stem cells in MDS and AML, and its detection could allow the prospective separation of leukemic stem cells from functionally normal hematopoietic stem cells in AML, thereby demonstrating the potential of anti-CD99 monoclonal antibodies as therapeutic agents. The gene discussed is CD99; the disease is acute myeloid leukemia.